Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Paion AG's Enterprise Value is $0.11 Mil.
Paion AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-14.34 Mil. Therefore, Paion AG's EV-to-FCF for today is -0.01.
The historical rank and industry rank for Paion AG's EV-to-FCF or its related term are showing as below:
PAIOF's EV-to-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 19.09 * Ranked among companies with meaningful EV-to-FCF only.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Paion AG's share price for today is $0.07.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paion AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.912.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Paion AG EV-to-FCF Related Terms
Paion AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Paion AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Paion AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paion AG EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Paion AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Paion AG's EV-to-FCF falls into.
Paion AG's current Enterprise Value is $0.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paion AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-14.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paion AG (PAIOF) has a EV-to-FCF of -0.01 as of Sep. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Paion AG and its competitors.
Is Paion AG's EV-to-FCF too high?
Paion AG's current EV-to-FCF is -0.01. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's EV-to-FCF compare to ZTS and NBIX?
Paion AG's EV-to-FCF of -0.01 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-FCF is 19.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.09, based on 573 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Paion AG and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paion AG's current EV-to-FCF is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current EV-to-FCF of -0.01. The current EV-to-FCF is -0.01. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Paion AG (PAIOF), the current EV-to-FCF is -0.01 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score
Get the complete analysis for PAIOF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAIOF has been successfully added to your 
